# 該合作旨在提升B細胞惡性腫瘤患者的治療選擇。

*biotech · news · 2026-06-08 · Benzinga*

## Key points

- Nurix將從羅氏獲得7億美元的前期付款，交易總價值高達23億美元。
- 根據合作協議，Bexobrutide將於2026年夏季進入慢性淋巴細胞白血病第三期臨床試驗。
- Nurix與羅氏將在美國共同推廣bexobrutide；利潤與虧損均分。
- 根據協議，開發成本由Nurix承擔40%，羅氏承擔60%。

The partnership aims to enhance treatment options for patients with B-cell malignancies, a sector projected to grow significantly, with the combined market expected to reach $41 billion by 2031. The collaboration with Roche will focus on bexobrutideg, which is set to enter Phase 3 clinical trials for treating chronic lymphocytic leukemia (CLL) in the summer of 2026. The partnership is seen as a strategic move to leverage Roche’s strengths in hematology and expand Nurix’s pipeline into immunology and neurology. Deal Terms Under the terms of the agreement, Nurix will receive an upfront cash payment of $700 million and is eligible to receive development, regulatory, and sales milestones for a potential total deal value of up to $2.3 billion. Development costs will be shared 40% by Nurix and 60% by Roche. The parties will equally split the profits and losses from U.S. commercialization. Nurix and Roche will co-commercialize bexobrutide in the U.S. across all indications. Outside the U.S., Roche will be responsible for commercialization, with Nurix receiving royalties ranging from the low to high teens. NRIX Technical Outlook: Bullish Trend With Key Levels Currently, Nurix Therapeutics is trading at $22.28, significantly above its 20-day simple moving average (SMA) of $16.42, indicating strong bullish momentum. The stock is also 30.3% above its 20-day SMA, 30.9% above its 50-day SMA, and 45% above its 200-day SMA, suggesting a robust upward trend. The moving average convergence divergence (MACD) is currently below its signal line, indicating that upside momentum may be cooling unless it can reclaim that baseline. This suggests that while the stock is experiencing a strong rally, traders should be cautious of potential pullbacks. Key Resistance: $22.50 — a nearby level where rebounds can stall, aligning with the recent swing high and a round-number area. Key Support: $17.50 — a nearby level where buyers previously stepped in, providing a potential safety net for the stock. NRIX Stock Price Activity: Nurix Therapeutics shares were up 51.23% at $22.14 during premarket trading on Monday, according to Benzinga Pro data. Image via Shutterstock/ Yomal2233

**Companies:** Roche, Nurix Therapeutics
**Countries:** United States

[Read the full story on Benzinga](https://www.benzinga.com/news/health-care/26/06/53056750/nurix-therapeutics-gains-ground-as-roche-partnership-targets-growing-b-cell-blood-cancer-market)

---

Canonical: https://newsio.io/zh-TW/n/4f6457d3-5456-4289-b76f-587dee6bb590/b2031410nurix7
Summarized by Newsio from Benzinga. https://newsio.io/how-it-works